Tim Anderson
Stock Analyst at B of A Securities
(3.74)
# 725
Out of 5,072 analysts
45
Total ratings
58.33%
Success rate
8.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Underperform | $543 → $627 | $784.61 | -20.09% | 3 | Oct 29, 2025 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $198 → $204 | $207.56 | -1.72% | 8 | Oct 15, 2025 | |
| PFE Pfizer | Maintains: Neutral | $28 → $30 | $25.71 | +16.69% | 3 | Oct 3, 2025 | |
| AMGN Amgen | Maintains: Underperform | $261 → $272 | $344.57 | -21.06% | 6 | Sep 26, 2025 | |
| APGE Apogee Therapeutics | Maintains: Buy | $78 → $87 | $70.39 | +23.60% | 1 | Aug 28, 2025 | |
| AARD Aardvark Therapeutics | Maintains: Buy | $26 → $25 | $9.67 | +158.53% | 3 | Aug 28, 2025 | |
| ABBV AbbVie | Maintains: Neutral | $200 → $204 | $227.66 | -10.39% | 7 | Apr 28, 2025 | |
| GILD Gilead Sciences | Maintains: Buy | $116 → $126 | $127.51 | -1.18% | 3 | Mar 5, 2025 | |
| MRNA Moderna | Maintains: Underperform | $41 → $34 | $25.01 | +35.95% | 2 | Feb 11, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $118 → $112 | $104.63 | +7.04% | 4 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $63 | $49.25 | +27.92% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $178 | $181.94 | -2.17% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $997 | $1,104.34 | -9.72% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $130.44 | - | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $93.32 | - | 1 | Sep 22, 2017 |
Regeneron Pharmaceuticals
Oct 29, 2025
Maintains: Underperform
Price Target: $543 → $627
Current: $784.61
Upside: -20.09%
Johnson & Johnson
Oct 15, 2025
Maintains: Neutral
Price Target: $198 → $204
Current: $207.56
Upside: -1.72%
Pfizer
Oct 3, 2025
Maintains: Neutral
Price Target: $28 → $30
Current: $25.71
Upside: +16.69%
Amgen
Sep 26, 2025
Maintains: Underperform
Price Target: $261 → $272
Current: $344.57
Upside: -21.06%
Apogee Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $78 → $87
Current: $70.39
Upside: +23.60%
Aardvark Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $26 → $25
Current: $9.67
Upside: +158.53%
AbbVie
Apr 28, 2025
Maintains: Neutral
Price Target: $200 → $204
Current: $227.66
Upside: -10.39%
Gilead Sciences
Mar 5, 2025
Maintains: Buy
Price Target: $116 → $126
Current: $127.51
Upside: -1.18%
Moderna
Feb 11, 2025
Maintains: Underperform
Price Target: $41 → $34
Current: $25.01
Upside: +35.95%
Merck & Co.
Feb 5, 2025
Maintains: Buy
Price Target: $118 → $112
Current: $104.63
Upside: +7.04%
Dec 10, 2024
Reinstates: Neutral
Price Target: $63
Current: $49.25
Upside: +27.92%
Dec 10, 2024
Reinstates: Neutral
Price Target: $178
Current: $181.94
Upside: -2.17%
Dec 10, 2024
Reinstates: Buy
Price Target: $997
Current: $1,104.34
Upside: -9.72%
May 9, 2022
Downgrades: Peer Perform
Price Target: n/a
Current: $130.44
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $93.32
Upside: -